Project Grant R01AR084830
Award Date 9/18/25
Completion Date 7/31/29
Dollars Obligated $448K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Virginia, USA
Similar Awards
- This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $1,292,847.00 to Advertent Biotherapeutics, Inc. to develop a novel agent called ADA011 for preventing fatty degeneration of muscles in limb girdle muscular dystrophy 2B (LGMD2B). The goal is to demonstrate the long-term efficacy of ADA011 in inhibiting muscle fatty degeneration and...
- This $313,148 Project Grant awarded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) will support the development of an in vivo imaging platform for myotonic dystrophy type 1 (DM1) drug discovery. The project aims to create novel fluorogenic RNA aptamer-based reporters that can detect drug-induced changes in toxic RNA foci formation and sequestration of the MBNL splicing...
- This federal Project Grant award of $1,091,199.00, funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to develop gene therapies for treating LAMA2-related dystrophy, a form of muscular dystrophy. The project, led by Rutgers, The State University of New Jersey, utilizes adeno-associated virus (AAV) delivery of genes encoding laminin-binding proteins to restore...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $439,791 Project Grant to The University of Texas Southwestern Medical Center on March 1, 2025 under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846). The grant supports research to investigate the molecular mechanisms of myoblast fusion, which is essential for skeletal muscle development and regeneration. The research aims to understand the cellular and...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $295,294 Phase I SBIR project grant (CFDA 93.846) to Gigamune, Inc. to develop a novel lentiviral gene delivery platform for in vivo delivery of the full-length dystrophin gene to muscle cells. The goal is to create an efficient and targeted approach for gene therapy to treat Duchenne muscular dystrophy, a severe genetic disorder causing muscle wasting. The project aims to leverage Gigamune's...
- This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to investigate the functional roles of microRNA-320 (miR-320) in skeletal muscle. The $374,204 award to The Leland Stanford Junior University will fully characterize a muscle-specific miR-320 knockout mouse model, examine the underlying mechanisms of the observed muscle wasting...
- The University of Florida was awarded a $599,496 project grant by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846). The objective of this 5-year project, with a performance period from September 15, 2025 to August 31, 2030, is to evaluate the potential of magnetic resonance (MR) measures of bioenergetics and microvascular function to track disease progression and...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $198,263 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846) to the Board of Regents of the University of Nebraska. The research project aims to investigate the role of the protein Mitsugumin 53 (MG53) in preventing muscle atrophy during periods of disuse, which can contribute to age-related sarcopenia and frailty. The research will explore how...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $1,037,340 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to The Broad Institute, Inc. to transform the Musculoskeletal Knowledge Portal (MSKKP) into an established biomedical knowledgebase. The project aims to integrate diverse 'omics datasets curated by musculoskeletal research experts, process the data through advanced genetic and genomic analysis...
- This $190,137 Cooperative Agreement was awarded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The agreement aims to bridge the gap between genetic testing and patient care for muscular dystrophies and myopathies by defining the clinical relevance of genes and genetic sequence variants associated with these disorders. Key efforts include evaluating the clinical validity of...